Allozyne
Allozyne is a clinical stage biotechnology company headquartered in Seattle's biotech and high tech innovation corridor. Allozyne was founded in 2005 by California Institute of Technology researchers, and was incubated by Accelerator Corporation. Its lead product candidate, AZ01, is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic degenerative disease characterized by demyelination of nerve fibers leading to severe nerve damage and increasing disability. Multiple sclerosis is estimated to affect 400,000 individuals in the US alone and 2.5 million worldwide. AZ01 is currently undergoing Phase I clinical trials in the US. Preclinical data indicates that AZ01 has the potential to be dosed once monthly compared to the current standard of care dosed anywhere from once daily to once per week.Allozyne's technology also enables the development of next generation antibody-drug conjugates (ADCs). This approach results in homogeneous ADC products that are stably conjugated.In 2014, Allozyne was acquired by MedImmune, based on its ADC technology. Financial terms of the transaction were not disclosed.
Excerpt from the Wikipedia article Allozyne (License: CC BY-SA 3.0, Authors, Images).Allozyne
Fairview Avenue East, Seattle Capitol Hill
Geographical coordinates (GPS) Address Nearby Places Show on map
Continue reading on Wikipedia
Geographical coordinates (GPS)
Latitude | Longitude |
---|---|
N 47.63415 ° | E -122.326789 ° |
Address
Fairview Avenue East 1600
98102 Seattle, Capitol Hill
Washington, United States
Open on Google Maps